KPV

Research-Grade

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Unlike the full-length hormone, KPV retains the anti-inflammatory signaling capacity while lacking significant melanocortin-receptor binding — meaning it suppresses inflammation without darkening the skin. The primary mechanism centers on inhibition of the NF-κB pathway. In cell culture and animal models of inflammatory bowel disease, KPV has reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), decreased neutrophil infiltration, and preserved mucosal barrier integrity. A 2020 study in *Biomaterials* demonstrated that oral delivery via hyaluronic-acid-functionalized nanoparticles concentrated KPV at inflamed colonic tissue in a mouse colitis model, significantly reducing disease activity index scores. KPV has also shown anti-inflammatory effects in keratinocyte and fibroblast models relevant to skin conditions including psoriasis and atopic dermatitis. Its small size (three amino acids) gives it favorable stability and bioavailability characteristics compared to full-length α-MSH. However, human clinical trial data remains absent — all published evidence is preclinical.